Today, Ningbo Minovar Pharmaceutical Co., Ltd. was successfully listed on the main board of the Shanghai Stock Exchange, becoming the first listed company specializing in the manufacture of medical specialty apis and pharmaceutical intermediates in Ningbo. The public issue of 30 million A-shares, the total share capital after the issue of 120 million shares, are tradable shares. After deducting the issuance cost, the funds raised by the issuance Institute will be used for the construction project of exporting solid preparations with an annual output of 3 billion tablets (pellets) and the construction project of drug research and development center.